Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Protea Biosciences Group, Inc. (PRGB)
|
Add to portfolio |
|
|
|
| Price: |
$0.04
| | Metrics |
| OS: |
305.2
|
M
| |
|
|
| Market cap: |
$10.7
|
M
| |
|
|
|
Net debt:
|
$9.19
|
M
| |
|
|
|
EV:
|
$19.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($344)
|
M
| |
|
|
|
EBIT
|
($25.6)
|
M
| |
|
|
| EPS |
($0.03)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| Revenues | 6.4 | 8.0 | 1.8 | 1.2 | -1.6 | -5.3 | 0.9 | 0.0 |
| Revenue growth | -20.8% | 354.9% | 44.5% | -176.6% | -69.9% | -686.2% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.9 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 6.4 | 8.0 | 0.9 | 0.3 | -1.6 | -5.3 | 0.9 | 0.0 |
| Gross margin | 100.0% | 100.0% | 50.7% | 23.8% | 100.0% | 100.0% | 100.1% | |
| Selling, general and administrative | 5.6 | 6.9 | 8.7 | 7.8 | 7.0 | 5.2 | 4.7 | 0.0 |
| Research and development | | | | | | | 5.5 | |
| EBIT | -25.8 | -12.0 | -10.7 | -10.3 | -9.0 | -10.8 | -9.3 | 0.0 |
| EBIT margin | -404.2% | -149.3% | -604.7% | -843.9% | 562.1% | 203.0% | -1021.6% | |
| Pre-tax income | -15.6 | -9.6 | -11.5 | -11.4 | -9.5 | -11.5 | -9.6 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9.6 | 0.0 |
| Net margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1058.4% | |
| |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ($0.58) | ($0.01) |
| Shares outstanding (diluted) | 136.1 | 109.7 | 67.8 | 45.0 | 29.0 | 20.9 | 16.5 | 3.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|